Prospects of Neutralizing Nanobodies Against SARS-CoV-2.
Since December 2019, the SARS-CoV-2 has erupted on a large scale worldwide and spread rapidly. Passive immunization of antibody-related molecules provides opportunities for prevention and treatment of high-risk patients and children. Nanobodies (Nbs) have many strong physical and chemical properties. They can be atomized, administered by inhalation, and can be directly applied to the infected site, with fast onset, high local drug concentration/high bioavailability, and high patient compliance (no needles). It has very attractive potential in the treatment of respiratory viruses. Rapid and low-cost development of Nbs targeting SARS-CoV-2 can quickly be achieved. Nbs against SARS-CoV-2 mutant strains also can be utilized quickly to prevent the virus from escaping. It provides important technical supports for the treatment of the SARS-CoV-2 and has the potential to become an essential medicine in the toolbox against the SARS-CoV-2.
['Chen|Fangfang|F|', 'Liu|Zhihong|Z|', 'Jiang|Fan|F|']
D000818:Animals D057134:Antibodies, Neutralizing D000914:Antibodies, Viral D000915:Antibody Affinity D001665:Binding Sites D000086382:COVID-19 D000939:Epitopes D006801:Humans D009500:Neutralization Tests D019151:Peptide Library D011485:Protein Binding D000086402:SARS-CoV-2 D061905:Single-Domain Antibodies
neutralizing SARS-CoV-2 nanobodies (VHH) phage display receptor binding domain